S. Latvala, S. Philipp, M. Lehtinen, L. Lehtoranta, A. Ouwehand
{"title":"Health Benefits of a Combination Probiotics; FlorMidabil™","authors":"S. Latvala, S. Philipp, M. Lehtinen, L. Lehtoranta, A. Ouwehand","doi":"10.37290/ijpp2641-7197.14:9-17","DOIUrl":null,"url":null,"abstract":"This review summarizes health benefits of a combination of a four-strain probiotic consisting of L. paracasei Lpc-37, B. lactis Bl-04, L. acidophilus La-14, and L. plantarum Lp-115. The safety of the individual strains for absence of transferable antibiotic resistance and adverse events in human intervention studies has been documented. The strains have been shown, both in vitro and in human studies, to survive gastro-intestinal transit and transiently colonize the intestine in a dose-dependent manner. In digestive health, the strains have shown to modulate the intestinal microbiota and reduce risk for both diarrhea and constipation. In vitro, animal and human studies have shown these strains to positively modulate many immune markers, in particular anti-inflammatory markers. These modifications also suggest a reduced risk for respiratory tract infections and seasonal respiratory allergies. The strains contributed positively to weight management in humans and reduced markers of metabolic syndrome in animal models. Finally, one of the strains (L. acidophilus La-14) was shown to colonize the vagina and contribute to reduced risk for recurrent bacterial vaginosis, vulvovaginal candidiasis and urinary tract infection. The combination of these four strains can therefore be expected to provide a broad spectrum of health benefits.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Probiotics and Prebiotics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37290/ijpp2641-7197.14:9-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
This review summarizes health benefits of a combination of a four-strain probiotic consisting of L. paracasei Lpc-37, B. lactis Bl-04, L. acidophilus La-14, and L. plantarum Lp-115. The safety of the individual strains for absence of transferable antibiotic resistance and adverse events in human intervention studies has been documented. The strains have been shown, both in vitro and in human studies, to survive gastro-intestinal transit and transiently colonize the intestine in a dose-dependent manner. In digestive health, the strains have shown to modulate the intestinal microbiota and reduce risk for both diarrhea and constipation. In vitro, animal and human studies have shown these strains to positively modulate many immune markers, in particular anti-inflammatory markers. These modifications also suggest a reduced risk for respiratory tract infections and seasonal respiratory allergies. The strains contributed positively to weight management in humans and reduced markers of metabolic syndrome in animal models. Finally, one of the strains (L. acidophilus La-14) was shown to colonize the vagina and contribute to reduced risk for recurrent bacterial vaginosis, vulvovaginal candidiasis and urinary tract infection. The combination of these four strains can therefore be expected to provide a broad spectrum of health benefits.
期刊介绍:
The International journal of Probiotics & Prebiotics publishes on online only in an open access format. This is a broad based international, interdisciplinary peer reviewed scientific journal for critical evaluation of research on prebiotics, probiotics and synbiotics. The major goal of this journal is to provide unbiased scientific data to students, researchers, healthcare providers, and the decision makers in the nutraceutical industry to help make informed choices about prebiotics, probiotics and synbiotics. To this end, the journal will publish original research articles and two types of review articles. First, we will publish a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, we will publish a critical evaluation of current human experimental data to help deliver products with medically proven use.